StockNews.com assumed coverage on shares of Pulmatrix (NASDAQ:PULM – Get Free Report) in a research note issued on Wednesday. The firm set a “hold” rating on the biotechnology company’s stock.
Pulmatrix Stock Up 3.0 %
Shares of PULM opened at $2.08 on Wednesday. The company has a market capitalization of $7.59 million, a P/E ratio of -0.54 and a beta of 0.92. The firm has a 50 day moving average of $1.86 and a 200 day moving average of $1.88. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $3.14.
Pulmatrix (NASDAQ:PULM – Get Free Report) last announced its quarterly earnings results on Thursday, March 28th. The biotechnology company reported ($0.57) earnings per share for the quarter. The firm had revenue of $2.20 million for the quarter. Pulmatrix had a negative net margin of 193.49% and a negative return on equity of 63.94%.
About Pulmatrix
Pulmatrix, Inc, a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
Read More
- Five stocks we like better than Pulmatrix
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Hasbro’s Management Made All the Right Calls This Quarter
- The 3 Best Blue-Chip Stocks to Buy Now
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- Quiet Period Expirations Explained
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Pulmatrix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmatrix and related companies with MarketBeat.com's FREE daily email newsletter.
